Adagrasib + Other Treatments for Solid Tumors

This trial tests the cancer drug adagrasib in individuals with solid tumors, such as non-small cell lung cancer and colorectal cancer. Researchers aim to evaluate the effectiveness of adagrasib alone or in combination with other treatments. Those who participated in a related study and continue to benefit from the treatment may find this trial suitable. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to significant findings.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that adagrasib, the treatment under study in this trial, generally has a manageable safety profile. In earlier studies, patients with advanced solid tumors who took adagrasib mostly experienced mild to moderate side effects. Common side effects included tiredness, nausea, and diarrhea, but these were usually not severe.

One study specifically found that for patients with KRAS G12C mutations, the side effects of adagrasib were manageable. While side effects occurred, they were not serious enough to outweigh the potential benefits, suggesting that many patients can tolerate adagrasib well.

Adagrasib is unique because it targets a specific mutation in the KRAS gene, which is a common driver in many solid tumors but has been notoriously difficult to treat. Unlike traditional chemotherapy that indiscriminately attacks rapidly dividing cells, Adagrasib precisely inhibits the mutant KRAS protein, potentially leading to better outcomes with fewer side effects. Researchers are excited about Adagrasib because it offers a targeted approach that could be more effective and safer for patients with specific genetic profiles compared to existing treatments.

Research has shown that adagrasib effectively treats solid tumors with the KRAS G12C mutation. Patients with this mutation have experienced significant survival benefits. Specifically, the average overall survival was about 14 months, and the time during which the cancer did not worsen was around 7 months. Tumor shrinkage or stabilization rates were also promising. In some patients, the response rate to adagrasib alone was 22%. In this trial, some participants will receive adagrasib alone, while others will receive it combined with cetuximab. Previous studies have shown that this combination increases the response rate to 39%. This suggests that adagrasib can be a strong option for people with these types of tumors.¹²³⁶⁷